Jorge L Gamboa1, Baback Roshanravan2, Theodore Towse3, Chad A Keller4, Aaron M Falck4, Chang Yu5, Walter R Frontera6,7, Nancy J Brown4, T Alp Ikizler8,9. 1. Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee jorge.gamboa@vanderbilt.edu. 2. Division of Nephrology, Department of Medicine, University of California, Davis, California. 3. Department of Biomedical Sciences, Grand Valley State University, Allendale, Michigan. 4. Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 5. Department of Biostatics, Vanderbilt University Medical Center, Nashville, Tennessee. 6. Department of Physical Medicine, Rehabilitation, and Sports Medicine, University of Puerto Rico, San Juan, Puerto Rico. 7. Department of Physiology and Biophysics, University of Puerto Rico, San Juan, Puerto Rico. 8. Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 9. Veterans Administration Tennessee Valley Healthcare System, Nashville, Tennessee.
Abstract
BACKGROUND AND OBJECTIVES: Patients with CKD suffer from frailty and sarcopenia, which is associated with higher morbidity and mortality. Skeletal muscle mitochondria are important for physical function and could be a target to prevent frailty and sarcopenia. In this study, we tested the hypothesis that mitochondrial dysfunction is associated with the severity of CKD. We also evaluated the interaction between mitochondrial function and coexisting comorbidities, such as impaired physical performance, intermuscular adipose tissue infiltration, inflammation, and oxidative stress. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Sixty-three participants were studied, including controls (n=21), patients with CKD not on maintenance hemodialysis (CKD 3-5; n=20), and patients on maintenance hemodialysis (n=22). We evaluated in vivo knee extensors mitochondrial function using 31P magnetic resonance spectroscopy to obtain the phosphocreatine recovery time constant, a measure of mitochondrial function. We measured physical performance using the 6-minute walk test, intermuscular adipose tissue infiltration with magnetic resonance imaging, and markers of inflammation and oxidative stress in plasma. In skeletal muscle biopsies from a select number of patients on maintenance hemodialysis, we also measured markers of mitochondrial dynamics (fusion and fission). RESULTS: We found a prolonged phosphocreatine recovery constant in patients on maintenance hemodialysis (53.3 [43.4-70.1] seconds, median [interquartile range]) and patients with CKD not on maintenance hemodialysis (41.5 [35.4-49.1] seconds) compared with controls (38.9 [32.5-46.0] seconds; P=0.001 among groups). Mitochondrial dysfunction was associated with poor physical performance (r=0.62; P=0.001), greater intermuscular adipose tissue (r=0.44; P=0.001), and increased markers of inflammation and oxidative stress (r=0.60; P=0.001). We found mitochondrial fragmentation and increased content of dynamin-related protein 1, a marker of mitochondrial fission, in skeletal muscles from patients on maintenance hemodialysis (0.86 [0.48-1.35] arbitrary units (A.U.), median [interquartile range]) compared with controls (0.60 [0.24-0.75] A.U.). CONCLUSIONS: Mitochondrial dysfunction is due to multifactorial etiologies and presents prior to the initiation of maintenance hemodialysis, including in patients with CKD stages 3-5.
BACKGROUND AND OBJECTIVES:Patients with CKD suffer from frailty and sarcopenia, which is associated with higher morbidity and mortality. Skeletal muscle mitochondria are important for physical function and could be a target to prevent frailty and sarcopenia. In this study, we tested the hypothesis that mitochondrial dysfunction is associated with the severity of CKD. We also evaluated the interaction between mitochondrial function and coexisting comorbidities, such as impaired physical performance, intermuscular adipose tissue infiltration, inflammation, and oxidative stress. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Sixty-three participants were studied, including controls (n=21), patients with CKD not on maintenance hemodialysis (CKD 3-5; n=20), and patients on maintenance hemodialysis (n=22). We evaluated in vivo knee extensors mitochondrial function using 31P magnetic resonance spectroscopy to obtain the phosphocreatine recovery time constant, a measure of mitochondrial function. We measured physical performance using the 6-minute walk test, intermuscular adipose tissue infiltration with magnetic resonance imaging, and markers of inflammation and oxidative stress in plasma. In skeletal muscle biopsies from a select number of patients on maintenance hemodialysis, we also measured markers of mitochondrial dynamics (fusion and fission). RESULTS: We found a prolonged phosphocreatine recovery constant in patients on maintenance hemodialysis (53.3 [43.4-70.1] seconds, median [interquartile range]) and patients with CKD not on maintenance hemodialysis (41.5 [35.4-49.1] seconds) compared with controls (38.9 [32.5-46.0] seconds; P=0.001 among groups). Mitochondrial dysfunction was associated with poor physical performance (r=0.62; P=0.001), greater intermuscular adipose tissue (r=0.44; P=0.001), and increased markers of inflammation and oxidative stress (r=0.60; P=0.001). We found mitochondrial fragmentation and increased content of dynamin-related protein 1, a marker of mitochondrial fission, in skeletal muscles from patients on maintenance hemodialysis (0.86 [0.48-1.35] arbitrary units (A.U.), median [interquartile range]) compared with controls (0.60 [0.24-0.75] A.U.). CONCLUSIONS:Mitochondrial dysfunction is due to multifactorial etiologies and presents prior to the initiation of maintenance hemodialysis, including in patients with CKD stages 3-5.
Authors: B H Goodpaster; C L Carlson; M Visser; D E Kelley; A Scherzinger; T B Harris; E Stamm; A B Newman Journal: J Appl Physiol (1985) Date: 2001-06
Authors: Thomas J Wilkinson; Douglas W Gould; Daniel G D Nixon; Emma L Watson; Alice C Smith Journal: Nephrol Dial Transplant Date: 2019-08-01 Impact factor: 5.992
Authors: Juan Pablo Arroyo; Elvis A Akwo; Andrew S Terker; Aseel Alsouqi; Gautam Bhave; Raymond C Harris; Adriana M Hung; T Alp Ikizler Journal: Kidney360 Date: 2021-07-08
Authors: Mingjian Shi; Chuan Wang; Hao Mei; Marinella Temprosa; Jose C Florez; Mark Tripputi; Jordi Merino; Loren Lipworth; Xiao-Ou Shu; Robert E Gerszten; Thomas J Wang; Joshua A Beckman; Jorge L Gamboa; Jonathan D Mosley; Jane F Ferguson Journal: J Am Heart Assoc Date: 2022-05-27 Impact factor: 6.106
Authors: Danielle L Kirkman; Natalie Bohmke; Salvatore Carbone; Ryan S Garten; Paula Rodriguez-Miguelez; Robert L Franco; Jason M Kidd; Antonio Abbate Journal: Am J Physiol Renal Physiol Date: 2020-12-07
Authors: Kyoungrae Kim; Erik M Anderson; Trace Thome; Guanyi Lu; Zachary R Salyers; Tomas A Cort; Kerri A O'Malley; Salvatore T Scali; Terence E Ryan Journal: Am J Physiol Renal Physiol Date: 2021-06-14